Pertussis FHA and Pertussis Fimbriae Antibodies

The Centers for Disease Control and Prevention intends to award a sole source firm fixed price purchase order to BioRad Inc, to obtain Pertussis FHA and Pertussis Fimbriae Antibodies. The MPIR Immunobiology laboratory is working on assay development for the detection of Pertussis antigen. In order to create an antigen detection assay, monoclonal recombinant antibodies need to be obtained. This will be done by using bacterial toxin derived from Bordetella Pertussis and a cell surface protein of Bordetella Pertussis. These two monoclonal recombinant antibodies will be generated through means of HuCAL technology for the purpose of using these antibodies to perform in-vitro research studies. Pertussis FHA and Pertussis Fimbriae antibodies are needed to capture and detect the disease causing pertussis antigen. The Fimbriae monoclonal recombinant antibodies should recognize the bacterial toxin derived from Bordetella Pertussis, and the FHA monoclonal recombinant antibodies should recognize a cell surface protein of the Bordetella pertussis. As additional specification, the antibodies shall not recognize Closely Related Antigens or Cross-Reactive Antigens (CRAs).

This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) (SAP) and 41 U.S.C. 3304(a)(1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals.

This notice of intent is not a request for competitive quotations; however, all quotations/responses received within five (5) days of the issuance of this notice will be considered by the government.  A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government.  Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.  Any quotation/response should be emailed to contract specialist at Qrz9@cdc.gov by 12:00pm 11 September, 2023.